Treatment of Right Basilic Vein DVT

Immediate Anticoagulation Strategy

The American College of Cardiology recommends starting anticoagulation immediately upon diagnosis to prevent pulmonary embolism 1

DOACs are strongly preferred over warfarin due to superior safety profile, no monitoring requirements, and at least equivalent efficacy 2, 1
Acceptable DOAC options include apixaban, rivaroxaban, edoxaban, and dabigatran 1

If DOACs are contraindicated or unavailable, start parenteral anticoagulation simultaneously with warfarin on day 1 and continue parenteral therapy for minimum 5 days AND until INR ≥2.0 for at least 24 hours 3, 1
Target INR range is 2.0-3.0 (target 2.5) 3

For provoked DVT, stop anticoagulation after exactly 3 months if the DVT occurred with a major reversible risk factor such as recent surgery or trauma 4, 2, 1
For unprovoked DVT or persistent risk factor, treat for at least 3-6 months, then offer extended anticoagulation with periodic reassessment of risks and benefits 4, 2, 1

The American Heart Association recommends treating upper extremity DVT with the same approach as lower extremity DVT 1
Parenteral anticoagulation is recommended for acute treatment if not using a DOAC with built-in loading dose 1

Do NOT use IVC filters in patients who can receive anticoagulation 1
Anticoagulation alone is preferred over catheter-directed thrombolysis for most DVT patients, including upper extremity DVT 1

If confirmed antiphospholipid syndrome is present, use adjusted-dose warfarin over DOACs during the treatment phase 2, 1
All patients should be assessed for extended-phase therapy at the conclusion of the 3-month treatment phase 2, 5
Patients receiving extended-phase anticoagulation should have this decision reevaluated at least annually and at times of significant health status changes 2
The decision to continue extended anticoagulation must balance recurrent VTE risk against bleeding risk and patient preference 2, 1